Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib

被引：3

作者：

Gadgeel, Shirish ^{[1
]}

Chen, Wei ^{[1
]}

Piotrowska, Zofia ^{[2
]}

Goldman, Jonathan W. ^{[3
]}

Wakelee, Heather ^{[4
]}

Camidge, D. Ross ^{[5
]}

Varga, Andrea ^{[6
]}

Yu, Helena ^{[7
]}

Papadimitrakopoulou, Vassiliki ^{[8
]}

Nea, Joel ^{[9
]}

Soria, Jean-Charles ^{[6
]}

Wozniak, Antoinette ^{[1
]}

Riely, Gregory ^{[10
]}

Narayanan, Vignesh ^{[11
]}

Mendenhal, Melody ^{[12
]}

Sequist, Lecia ^{[13
]}

机构：

[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[2] Mgh Canc Ctr, Hematol Oncol, Boston, MA USA

[3] UCLA, Med Hematol Oncol, Santa Monica, CA USA

[4] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[5] Univ Colorado, Med Oncol, Aurora, CO USA

[6] Gustav Roussy, Med Oncol, Villejuif, France

[7] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[8] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[9] Stanford Univ, Stanford Canc Intitute, Med Oncol, Stanford, CA 94305 USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Univ Colorado, Aurora, CO USA

[12] UCLA, Med Hematol Oncol, Santa Monica, CA USA

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

osimertinib; rociletinib; EGFR; T790M;

D O I：

10.1016/j.jtho.2016.11.1783

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-115

引用

页码：S1263 / S1263

页数：1

共 50 条

[1] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
Paulina Bracht, Jillian Wilhelmina
Karachaliou, Niki
Berenguer, Jordi
Pedraz-Valdunciel, Carlos
Filipska, Martyna
Codony-Servat, Carles
Codony-Servat, Jordi
Rosell, Rafael
[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
[2] Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).
Garon, Edward B.
Leighl, Natasha B.
Rizvi, Naiyer A.
Blumenschein, George R.
Balmanoukian, Ani Sarkis
Eder, Joseph Paul
Goldman, Jonathan Wade
Hui, Rina
Soria, Jean-Charles
Gangadhar, Tara C.
Sun, Jong-Mu
Patnaik, Amita
Gubens, Matthew A.
Lubiniecki, Gregory M.
Zhang, Jin
Niewood, Michelle
Emancipator, Kenneth
Dolled-Filhart, Marisa
Hanson, Mary Elizabeth
Gandhi, Leena
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
Alsharedi, M.
Bukamur, H.
Elhamdani, A.
[J]. DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
[4] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
Meinrenken, Susanne
[J]. PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
[5] Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC).
Mata, Danilo Giffoni de Mello Morais
Romero, Maria Luisa
Gonzalez, Carlos Amir Carmona
Thawer, Alia
Doherty, Mark
Menjak, Ines B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
van Veggel, B.
Santos, J. F. Vilacha Madeira R.
Hashemi, S. M. S.
Paats, M. S.
Monkhorst, K.
Heideman, D. A. M.
Groves, M.
Radonic, T.
Smit, E. F.
Schuuring, E.
van der Wekken, A. J.
de Langen, A. J.
[J]. LUNG CANCER, 2020, 141 : 9 - 13
[7] Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Hong, S.
Ahn, H. J.
Kim, K. H.
Lee, S. S.
Lee, Y. G.
Yuh, Y. J.
Cheon, P. I.
Chae, Y. S.
Jang, T. W.
Kang, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2134 - S2135
[8] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
Garcia Samblas, Victoria
Fernandez Madrigal, Laura
Rodriguez Garces, Maria Yeray
Inoriza, Angel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
Inagaki, Yuji
Tamiya, Akihiro
[J]. LUNG CANCER, 2020, 148 : 179 - 180
[10] Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
Gadgeel, S.
Soria, J. C.
Goldman, J. W.
Wakelee, H.
Camidge, D. R.
Yu, H.
Varga, A.
Solomon, B.
Oxnard, G. R.
Ou, S. H.
Papadimitrakopoulou, V.
Liu, S. V.
Reckamp, K.
Spira, A.
Piotrowska, Z.
Despain, D.
Karlovich, C.
Yurasov, S.
Sequist, L. V.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S628 - S628

← 1 2 3 4 5 →